Loading...
•
Dec 31, 2024
Biogen Q4 2024 Earnings Report
Key Takeaways
Biogen reported Q4 2024 revenue of $2.46 billion, a 3% increase year-over-year. GAAP diluted EPS was $1.83, up 7% YoY, while Non-GAAP diluted EPS reached $3.44, up 17% YoY. Growth was primarily driven by rare disease revenue and biosimilars, which offset declines in multiple sclerosis products.
Revenue by Segment
Revenue by Geographic Location
Forward Guidance
Biogen expects FY 2025 revenue to decline by a mid-single digit percentage, driven by further declines in multiple sclerosis product revenue, partially offset by growth in product launches.
Positive Outlook
- Continued revenue growth from LEQEMBI and SKYCLARYS.
- FDA approval for LEQEMBI intravenous maintenance dosing.
- Cost reductions through the Fit for Growth program.
- Pipeline expansion with key late-stage assets.
- Stable operating margin expected for 2025.
Challenges Ahead
- Declining multiple sclerosis product revenue.
- Foreign exchange headwinds impacting financials.
- Increased competition in rare disease treatments.
- Uncertainty around Alzheimer’s collaboration revenue.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...